Approximately 75% of cord blood transplant (CBT) recipients experience human herpes virus-6 (HHV-6) reactivation. Considering the immunomodulatory effects of HHV-6, we hypothesized that early HHV-6 reactivation may influence the risk of relapse of the underlying hematologic malignancy. In 152 CBT recipients with hematological malignancies, we determined the association between HHV-6 reactivation by day 128 and 2-year cumulative incidence of relapse. In univariate analysis, the absence of HHV-6 reactivation (n 5 32) was associated with less relapse (26 [18-35]% vs. 7 [0-17]% in groups with vs. without HHV-6 reactivation, respectively; P 5 .03). This difference was due to a remarkably low relapse incidence among patients without HHV-6 reactivation. In multivariable analysis, the absence of HHV-6 reactivation was associated with less relapse (hazard ratio [95% confidence interval]: 0.2 [0.05-0.9], P 5 .03). This association was independent of patient-, disease-, and transplant-related characteristics known to influence the risk of relapse.
| I N T R O D U C T I O N
Human herpes virus-6 (HHV-6), a ubiquitous virus with pervasive immunomodulatory effects, 1 reactivates in 75% of cord blood transplant (CBT) recipients at a median of 2-3 weeks after transplant. [2] [3] [4] In contrast to the suggested role of cytomegalovirus (CMV) reactivation in protection against relapse, 5 there is little data on the potential impact of HHV-6 reactivation on relapse. Here, we show that CBT recipients without HHV-6 reactivation by day 128 experience very low relapse rates. Considering the rapid reconstitution of natural killer (NK) cells after CBT and their antiviral and anti-tumor effects, we compared day 128 NK cell reconstitution between groups with vs. without HHV-6 reactivation. In contrast to CMV, 6 human immunodeficiency virus (HIV), 7 hantavirus, 8 and chikungunya, 9 but similar to herpes simplex virus-2 (HSV-2) 10 and Epstein-Barr virus (EBV), 11 HHV-6 reactivation did not alter the NK cell repertoire. Similarly, CD4 1 and CD8 1 T-cell reconstitution at day 128 was not different between the groups.
| M E T H O D S
We studied all CBT recipients with a hematological malignancy at our center (July 30, 2010 to May 24, 2017 ) who survived at least 28 days after transplant without relapse. Patients who did not have HHV-6 surveillance (at least once every 2 weeks in the first 4 weeks post-transplant) and 3 patients with chromosomally integrated HHV-6 were excluded. Early HHV-6 reactivation was defined as 1 positive whole The Kaplan-Meier method with a log-rank test was used to estimate survival probabilities and compare the groups. The cumulative incidence function was used to estimate relapse and graft-versus-host disease (GVHD) probabilities with nonevent mortality as a competing risk. Relapse was considered a competing risk for nonrelapse mortality.
The groups were compared using Fine and Gray competing risks regression analyses. R 3.4 was used for analysis, with 2-sided P values and a significance threshold of .05.
| R E S U LTS
Characteristics of the groups with (n 5 120) vs. without (n 5 32) HHV-6 reactivation and univariate analysis of relapse are shown in Table 1 .
Of the 152 patients, 31 relapsed at a median (range) of 137 days after transplant, including 29 patients with HHV-6 reactivation and 2 patients without HHV-6 reactivation. The underlying diseases in relapsed patients with HHV-6 reactivation were acute lymphoblastic leukemia (ALL; n 5 10), acute myeloid leukemia (n 5 10), multiple myeloma (n 5 4), non-Hodgkin lymphoma (n 5 3), Hodgkin lymphoma (n 5 1), and chronic lymphocytic leukemia (n 5 1). The underlying diseases in relapsed patients without HHV-6 reactivation were multiple myeloma (n 5 1) and ALL (n 5 1). In univariate analysis, the only significant predictor of 2-year relapse was HHV-6 reactivation by day 128 
| D IS C U S S I O N
We focused on HHV-6 reactivation until day 128 because the median time to HHV-6 reactivation is 2-3 weeks, [2] [3] [4] and NK cells, known to contribute to the GvT effect, 15 reconstitute within a few weeks after transplant. 16, 17 In addition, several viral infections (CMV, 11 Hantavirus, has best been demonstrated for CMV. 6, 18, 19 Furthermore, posttransplant expansion of CMV-induced adaptive NK cells has been associated with less leukemia relapse. 20 In this study, however, the number and frequency of NK cells (overall and different subsets) at day 128
were similar in the groups with vs. without HHV-6 reactivation. This novel result characterizes HHV-6, along with HSV-2 10 and EBV, 11 as viruses that do not alter the NK cell repertoire, and argues against direct infectivity of HHV-6 to NK cells 21 as an explanation for the observed association between HHV-6 reactivation and relapse.
Similarly, we did not find significant differences in day 128 Tcell reconstitution between the groups with vs. without HHV-6 reactivation.
Although we did not find numerical T and NK cell differences between the groups with vs. without HHV-6 reactivation, HHV-6-induced functional differences may have been present and explain differences in GvT effect. The principal cellular receptor for HHV-6 is CD46, a ubiquitously expressed regulator of complement activation and a bridge between innate and adaptive arms of the immune system. 22 Although CD4 infection, 23 dendritic cells can also be infected. 24 CD34 1 stem cells are susceptible to HHV-6 infection and can transfer the virus to differentiating hematopoietic cells. 25, 26 Differentiation and replication of hematopoietic precursors are suppressed by HHV-6. 27, 28 Finally, the cytokine milieu changes after HHV-6 infection; IL-2 production is decreased 29 while the production of IL-1b, TNF-a, and IL-18 is increased. 29, 30 Some of these mechanisms may alter the GvT effect and the risk of relapse.
The incidence of relapse in our patients with HHV-6 reactivation was similar to the expected overall relapse rate after CBT from previous reports, 31, 32 suggesting that patients without HHV-6 reactivation may represent a unique subset with particularly powerful GvT function.
A graft-intrinsic characteristic may confer protection against both HHV-6 reactivation and relapse.
Consistent with several previous reports, 33-37 the incidence of grade II-IV acute GVHD by day 1180 was marginally significantly higher among patients with HHV-6 reactivation by day 128 (33 [23- 42]% vs. 14 [0-28]%, respectively; P 5 .07). We explored the possibility that less steroid exposure due to the lower incidence of acute GVHD permitted a more powerful GvT effect and reduced relapse in patients without HHV-6 reactivation. We defined steroid exposure as 1 mg/ kg/day of prednisone (or equivalent) for 7 days. This analysis was unremarkable; 21 of the 80 (26%) unexposed vs. 12 of the 72 (17%) exposed patients relapsed (P 5 .17), arguing against steroid exposure being a contributor to relapse in the group with HHV-6 reactivation. A large recent study demonstrated an association between grade II-IV acute GVHD and less relapse after single CBT. 38 This finding combined with our results further suggest that acute GVHD is likely not involved in the causation pathway between HHV-6 reactivation and relapse.
Two previous studies reported data on the association between HHV-6 reactivation and relapse. 33, 37 In the study by Aoki et al. 33 (n 5 236), cord blood was the graft source in 27% 33 of patients and HHV-6 surveillance was performed weekly (starting within the first 2 weeks after transplant) until week 4 after transplant. HHV-6 reactivation within the first 4 weeks after transplant was not associated with 3-year relapse. In the study by Dulery et al. 37 (n 5 235), cord blood was the graft source in 14% 37 of the patients. HHV-6 surveillance started at a nonuniform time point within the first month after transplant and was symptom-triggered between month 1 and month 6 posttransplant. HHV-6 reactivation within the first 6 months after transplant was not associated with 6-month relapse. We included only CBT recipients and used strict criteria to define HHV-6 reactivation based on the time of initiation and frequency of surveillance. Furthermore, our largely stable CBT practice specifics such as using a uniform conditioning regimen (Table 1) over the study period enhanced the homogeneity of our target population. These characteristics likely contributed to our ability to detect an association not observed in previous studies.
In conclusion, we demonstrated that CBT recipients without early HHV-6 reactivation by day 128 have very low relapse rates and HHV-6 reactivation does not alter early NK cell or T-cell reconstitution. A potential limitation of our analysis is related to disease heterogeneity. Although the DRI distribution was similar between the groups with vs. without HHV-6 reactivation, the GvL effect (and thus risk of relapse) depends on specific disease type and a more homogenous cohort would be desirable in future confirmatory analyses. While understanding the precise mechanisms of our findings and their generalizability to noncord allografts require more research, these results permit identification of a subset of CBT recipients at day 128 with remarkably low risks of relapse. 
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